Wells Fargo & Company MN lowered its stake in Phibro Animal Health Corp (NASDAQ:PAHC) by 21.4% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 197,998 shares of the company’s stock after selling 54,041 shares during the period. Wells Fargo & Company MN owned approximately 0.49% of Phibro Animal Health worth $6,291,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. FNY Investment Advisers LLC raised its stake in Phibro Animal Health by 73.3% during the second quarter. FNY Investment Advisers LLC now owns 1,040 shares of the company’s stock worth $33,000 after buying an additional 440 shares during the last quarter. Financial Gravity Wealth Inc. purchased a new stake in Phibro Animal Health in the 2nd quarter valued at $38,000. Truvestments Capital LLC grew its holdings in Phibro Animal Health by 324.5% in the 2nd quarter. Truvestments Capital LLC now owns 4,580 shares of the company’s stock valued at $146,000 after buying an additional 3,501 shares in the last quarter. BNP Paribas Arbitrage SA grew its holdings in Phibro Animal Health by 926.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,713 shares of the company’s stock valued at $156,000 after buying an additional 4,254 shares in the last quarter. Finally, Advisors Asset Management Inc. grew its holdings in Phibro Animal Health by 136.0% in the 1st quarter. Advisors Asset Management Inc. now owns 5,984 shares of the company’s stock valued at $197,000 after buying an additional 3,448 shares in the last quarter. Hedge funds and other institutional investors own 51.70% of the company’s stock.

Several analysts have issued reports on PAHC shares. Bank of America dropped their target price on Phibro Animal Health from $29.00 to $18.00 and set an “underperform” rating for the company in a report on Thursday, August 29th. Credit Suisse Group restated a “neutral” rating and issued a $25.00 target price (down from $31.00) on shares of Phibro Animal Health in a report on Wednesday, August 28th. TheStreet cut Phibro Animal Health from a “b-” rating to a “c+” rating in a report on Tuesday, September 10th. Barclays lowered their price target on Phibro Animal Health from $25.00 to $18.00 and set an “underweight” rating for the company in a report on Thursday, August 29th. Finally, Morgan Stanley upgraded Phibro Animal Health from an “underweight” rating to an “equal” rating and increased their price target for the stock from $21.00 to $30.00 in a report on Thursday, September 5th. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $26.60.

In other Phibro Animal Health news, Director E Thomas Corcoran bought 5,000 shares of Phibro Animal Health stock in a transaction dated Friday, August 30th. The stock was bought at an average price of $21.21 per share, for a total transaction of $106,050.00. Following the completion of the acquisition, the director now directly owns 15,000 shares of the company’s stock, valued at $318,150. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 50.29% of the stock is owned by corporate insiders.

Shares of NASDAQ PAHC traded up $1.14 during trading on Monday, reaching $22.54. The company had a trading volume of 5,406 shares, compared to its average volume of 340,962. Phibro Animal Health Corp has a twelve month low of $20.00 and a twelve month high of $44.99. The stock has a market capitalization of $891.92 million, a PE ratio of 14.74, a price-to-earnings-growth ratio of 4.20 and a beta of 0.82. The stock has a 50-day moving average price of $27.61 and a two-hundred day moving average price of $30.25. The company has a current ratio of 3.02, a quick ratio of 1.74 and a debt-to-equity ratio of 1.45.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Tuesday, August 27th. The company reported $0.33 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.34 by ($0.01). Phibro Animal Health had a return on equity of 29.99% and a net margin of 6.59%. The company had revenue of $203.90 million during the quarter, compared to analyst estimates of $206.00 million. During the same period last year, the firm earned $0.46 earnings per share. The business’s revenue was down 3.7% compared to the same quarter last year. On average, sell-side analysts predict that Phibro Animal Health Corp will post 1.12 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 25th. Stockholders of record on Wednesday, September 4th will be issued a $0.12 dividend. The ex-dividend date is Tuesday, September 3rd. This represents a $0.48 dividend on an annualized basis and a dividend yield of 2.13%. Phibro Animal Health’s payout ratio is currently 31.37%.

Phibro Animal Health Profile

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.

Further Reading: What is a short straddle?

Want to see what other hedge funds are holding PAHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phibro Animal Health Corp (NASDAQ:PAHC).

Institutional Ownership by Quarter for Phibro Animal Health (NASDAQ:PAHC)

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.